The EMA is the source of the information in this article:https://bit.ly/3zG7cfrFrom Medscape (July 14, 2024)--"EMA Warns of Anap...

I'm not sure why the world needs so many generic versions of glatiramer acetate but there's a new one that has just been approve...

From Nature (February 8, 2025)--"Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database...

Now that there is a plethora of MS drugs available, those who enjoy entertaining spectacles can watch while the drug companies d...

I've been taking Glatopa for over a year and a half now and have noticed that the initial reactions (burning, pain, swelling and...

Glatiramer acetate (Copaxone) users are familiar with the IPIR (immediate post-injection reaction) that some people have shortly...

Referral to new thread under "Copaxone":https://msspeaks.createaforum.com/copaxone-(glatiramer-acetate)/autoinjector-cross-compa...

From NeurologyLive (May 16, 2024)--"Cross-compatibility issues with autoinjectors highlighted in new FDA labelling update of gla...

This new MS drug, to be marketed for RRMS and PPMS, seems to be a "depot" version of glatiramer acetate (Copaxone), injected eve...

I took Copaxone for nearly 3 years but stopped taking it 10 years ago.In mid-December I began the generic three-times-a-week for...

I've been taking Glatopa for a couple of years now, and the prescribing neuro regularly orders lab work. It looks as if it is a ...

From an e-mail from Mapi Pharma. Glatiramer acetate in an extended-release form, taken in a 40mg dose every 28 days via an intra...

From PubMed, January 24, 2020--"Drug-induced liver injury associated with the biosimilar glatiramer acetate (Clift)":https://www...

PubMed has listed several studies  from a report called LiverTox: Clinical and Research Information on Drug-Induced Liver Injury...

This report, in Multiple Sclerosis International (January 19, 2019),   seems to have been funded by Teva, the makers of Copaxone...

From the MS Research Roundup, MS Discovery Forum, October 3, 2014:QuoteCopaxone Meets Its Match in GenericIn the United States, ...

Presented at the CMSC conference May 29, 2015:QuotePatient Experience and Tolerance of New Glatiramer DosingLynda R Hillman, DNP...

Presented at the recent annual AAN conference in Washington, DC:Quote[P7.218] Patient experience with glatiramer acetate 40 mg/1...

It's unusual to find a research article where the day-to-day practical problems of coping with MS injections are addressed, but ...